Mittwoch, 18. Oktober 2017


  • Pressemitteilung BoxID 157535

New Roche NimbleGen Service Now With 2 micron Scanning on the MS 200 Scanner

Madison, WI, USA, (lifePR) - Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) is pleased to announce that its Service Business (via its Iceland service facility, located in Reykjavik, Iceland), will now offer 2 micron resolution scanning on the NimbleGen MS 200 Microarray Scanner for Comparative Genomic Hybridization arrays (2.1M, 3x720K, and 12x135K formats) and Gene Expression arrays (12x135K format). The NimbleGen MS 200 Microarray Scanner is the latest enhancement to the Roche NimbleGen microarray workflow and provides high throughput processing optimized for current high resolution NimbleGen microarrays as well as the next-generation NimbleGen arrays of tomorrow.

The increase in resolution to 2 micron scanning in the company's Service offering now allows customers that access NimbleGen products an increase in the signal-to-noise ratio for their service experiments. Increases in signal-to-noise on NimbleGen Comparative Genomic Hybridization (CGH) arrays can ultimately lead to more confidence in detecting copy number variations and genomic breakpoints. For Gene Expression, this increase can lead to greater confidence in determining differential expression of the genome of interest.

"Roche NimbleGen is proud to introduce the high resolution scanning power of the MS 200 and to make it globally available for our Service customers on the CGH and Gene Expression suite of products. Accessible through our core service business in Iceland or via one of our numerous certified service providers throughout the world, customers can feel confident that they will receive high quality data and service from a company they know and trust," adds Dr. Frank Pitzer, CEO for Roche NimbleGen, Inc.

For more information about Roche NimbleGen, please visit www.nimblegen.com

NIMBLEGEN is a trademark of Roche. Other brands or product names are trademarks of their respective holders.

Roche Diagnostics GmbH

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80'000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Diese Pressemitteilungen könnten Sie auch interessieren

Diabetes-Barcamp – erstmals in Deutschland

, Gesundheit & Medizin, Verlag Kirchheim & Co GmbH

Ein neuartiges Live-Forum mit vielen Möglichkeiten, selbst Themen zu entwickeln und sich darüber auszutauschen – das ist das #DiabetesBarcamp...

Duisburger Beispiel 2017 für Borderline-Projekte

, Gesundheit & Medizin, NOVITAS BKK

Es gibt Erkrankungen, über die redet man nicht gern. Umso wichtiger ist dann, dass andere es tun. Unter der Schirmherrschaft von Oberbürgermeister...

Biologische Arzneimittel: Mehr Therapiechancen für Patienten

, Gesundheit & Medizin, QuintilesIMS

Der Umsatz mit biotechnologisch hergestellten Medikamenten ist in den letzten zehn Jahren sowohl weltweit als auch in Deutschland etwa doppelt...

Disclaimer